Literature DB >> 7582530

Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline.

B A Kenny1, D H Chalmers, P C Philpott, A M Naylor.   

Abstract

1. The affinities of a number of alpha 1-adrenoceptor antagonists were determined by displacement of [3H]-prazosin binding from cloned human alpha 1A-adrenoceptors (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and rat alpha 1D-adrenoceptors, stably expressed in rat-1 fibroblasts. Functional affinity estimates for these compounds were also determined from noradrenaline-mediated contractions of rat aorta. 2. BMY 7378 displayed high affinity for cloned human alpha 1D-adrenoceptors (pKi = 8.2 +/- 0.10) and was selective over alpha 1A (pKi = 6.2 +/- 0.10) and alpha 1B subtypes (6.7 +/- 0.11). WB 4101, benoxathian and phentolamine displayed high affinity for alpha 1A and alpha 1D adrenoceptors compared to the alpha 1B subtype. Spiperone displayed high affinity and selectivity for alpha 1B adrenoceptors (pKi 8.8 +/- 0.16). 5-Methyl-urapidil was selective for cloned alpha 1A adrenoceptors. 3. Comparative binding affinities (pKi) for compounds at cloned human and rat1D adrenoceptors were almost identical (r = 0.99, slope = 1.08). 4. Prazosin, doxazosin and 5-methyl-urapidil were potent, competitive antagonists of noradrenaline-mediated contractions of rat aorta (pA2 values of 9.8, 8.8 and 7.8 respectively). The selective alpha 1D antagonist BMY 7378 was also a potent antagonist on rat aorta (pKB = 8.3 +/- 0.1) but the interaction of this compound was not consistent with competitive antagonism at a single population of receptors. 5. Functional affinities for compounds determined against noradrenaline-mediated contractions of rat aorta correlated well with binding affinities at cloned alpha 1D-adrenoceptors (r = 0.96), but not with alpha 1A (r = 0.61) or alpha 1B (r = 0.46) subtypes. 6. Noradrenaline-mediated contractions of rat aorta were sensitive to the alkylating effects of chlorethylclonidine (CEC). CEC (10 microM) caused a small rightward shift in the noradrenaline concentration-response curve. CEC at 100 microM caused a further shift and suppression of the maximum response to noradrenaline.7. The results of this study suggest that noradrenaline predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an alphalD-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582530      PMCID: PMC1908994          DOI: 10.1111/j.1476-5381.1995.tb15907.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Identification of a single alpha 1-adrenoceptor corresponding to the alpha 1A-subtype in rat submaxillary gland.

Authors:  A D Michel; D N Loury; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

2.  THE UPTAKE OF ATROPINE AND RELATED DRUGS BY INTESTINAL SMOOTH MUSCLE OF THE GUINEA-PIG IN RELATION TO ACETYLCHOLINE RECEPTORS.

Authors:  W D PATON; H P RANG
Journal:  Proc R Soc Lond B Biol Sci       Date:  1965-08-24

Review 3.  Structure and function of alpha-adrenoceptors.

Authors:  R R Ruffolo; A J Nichols; J M Stadel; J P Hieble
Journal:  Pharmacol Rev       Date:  1991-12       Impact factor: 25.468

4.  Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA.

Authors:  D M Perez; M T Piascik; R M Graham
Journal:  Mol Pharmacol       Date:  1991-12       Impact factor: 4.436

Review 5.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

6.  Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor.

Authors:  M T Piascik; M S Sparks; T A Pruitt; E E Soltis
Journal:  Eur J Pharmacol       Date:  1991-07-09       Impact factor: 4.432

7.  Interaction of subtype-selective antagonists with alpha 1-adrenergic receptor binding sites in rat tissues.

Authors:  C D Han; K P Minneman
Journal:  Mol Pharmacol       Date:  1991-10       Impact factor: 4.436

8.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5.

Authors:  J W Lomasney; S Cotecchia; W Lorenz; W Y Leung; D A Schwinn; T L Yang-Feng; M Brownstein; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

Review 9.  Subtypes of alpha 1- and alpha 2-adrenergic receptors.

Authors:  D B Bylund
Journal:  FASEB J       Date:  1992-02-01       Impact factor: 5.191

10.  Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle.

Authors:  I Muramatsu; T Ohmura; S Kigoshi; S Hashimoto; M Oshita
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

View more
  44 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  The potential of metabolomic analysis techniques for the characterisation of α1-adrenergic receptors in cultured N1E-115 mouse neuroblastoma cells.

Authors:  Maria I Wenner; Garth L Maker; Linda F Dawson; Peter D Drummond; Ian Mullaney
Journal:  Cytotechnology       Date:  2015-09-25       Impact factor: 2.058

3.  Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor.

Authors:  A Cavalli; A L Lattion; E Hummler; M Nenniger; T Pedrazzini; J F Aubert; M C Michel; M Yang; G Lembo; C Vecchione; M Mostardini; A Schmidt; F Beermann; S Cotecchia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

4.  Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice.

Authors:  Chihiro Hosoda; Akito Tanoue; Mari Shibano; Yoshio Tanaka; Masami Hiroyama; Taka-aki Koshimizu; Susanna Cotecchia; Tadaichi Kitamura; Gozoh Tsujimoto; Katsuo Koike
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

5.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.

Authors:  J S Morton; C J Daly; V M Jackson; J C McGrath
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

7.  Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors.

Authors:  Bei Sun; Ekaterina Kintsurashvili; Deborah Ona; Ivana Ignjacev-Lazich; Irene Gavras; Haralambos Gavras
Journal:  Vascul Pharmacol       Date:  2007-01-23       Impact factor: 5.773

8.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

9.  Formalin hindpaw injection induces changes in the [3H]prazosin binding to alpha1-adrenoceptors in specific regions of the mouse brain and spinal cord.

Authors:  I Nalepa; J Vetulani; V Borghi; M Kowalska; B Przewłocka; F Pavone
Journal:  J Neural Transm (Vienna)       Date:  2005-02-22       Impact factor: 3.575

10.  Alpha(1D)-adrenergic receptor insensitivity is associated with alterations in its expression and distribution in cultured vascular myocytes.

Authors:  Lin-lin Fan; Shuang Ren; Hong Zhou; Ying Wang; Ping-xiang Xu; Jun-qi He; Da-li Luo
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.